Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cyclosporine and COVID-19: Risk or favorable?

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-A multicenter analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of genital warts in renal transplant recipients-A registry-based, prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Decreasing incidence of cancer after liver transplantation-A Nordic population-based study over 3 decades

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Blood chimerism in dizygotic monochorionic twins during five years observation

    Research output: Contribution to journalJournal articleResearch

  1. One-year mortality increases four-fold in frail patients undergoing cardiac surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dapagliflozin in Patients with Chronic Kidney Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The coronavirus disease 2019 (COVID-19) pandemic is declared a global health emergency. COVID-19 is triggered by a novel coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Baseline characteristics of admitted patients with COVID-19 show that adiposity, diabetes, and hypertension are risk factors for developing severe disease, but so far immunosuppressed patients who are listed as high-risk patients have not been more susceptible to severe COVID-19 than the rest of the population. Multiple clinical trials are currently being conducted, which may identify more drugs that can lower mortality, morbidity, and burden on the society. Several independent studies have convincingly shown that cyclosporine inhibit replication of several different coronaviruses in vitro. The cyclosporine-analog alisporivir has recently been shown to inhibit SARS-CoV-2 in vitro. These findings are intriguing, although there is no clinical evidence for a protective effect to reduce the likelihood of severe COVID-19 or to treat the immune storm or acute respiratory distress syndrome (ARDS) that often causes severe morbidity. Here, we review the putative link between COVID-19 and cyclosporine, while we await more robust clinical data.

Original languageEnglish
JournalAmerican Journal of Transplantation
Volume20
Issue number11
Pages (from-to)2975-2982
Number of pages8
ISSN1600-6135
DOIs
Publication statusPublished - 1 Nov 2020

    Research areas

  • clinical research/practice, immunosuppressant - calcineurin inhibitor (CNI), immunosuppression/immune modulation, infection and infectious agents - viral, infectious disease, organ transplantation in general

ID: 61066298